24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
GEMLIEVA 200MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | GEMLIEVA 200MG |
|---|---|
| Composition | Gemcitabine for Injection IP 200mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
GEMLIEVA 200MG (Gemcitabine for Injection IP 200mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
GEMLIEVA RTU 200 MG (Gemcitabine for Injection IP 200 mg) is a prescription anticancer medication containing Gemcitabine 200 mg, a well-established chemotherapy medicine used in the treatment of various solid tumors and advanced cancers. The term RTU (Ready-to-Use) indicates that the formulation is designed for convenient clinical administration, helping healthcare professionals prepare and deliver treatment efficiently while maintaining accuracy and safety.
Gemcitabine belongs to a class of medicines known as antimetabolites. It works by interfering with DNA synthesis in rapidly dividing cancer cells, preventing them from growing and multiplying. By disrupting the cancer cell cycle, Gemcitabine helps slow disease progression and supports effective cancer management.
Cancer develops when abnormal cells grow uncontrollably and spread to surrounding tissues or distant organs. These cancer cells depend on continuous DNA replication for survival and expansion. GEMLIEVA RTU 200 MG targets this process by incorporating itself into the DNA of malignant cells and blocking further replication, ultimately leading to cancer cell death.
GEMLIEVA RTU 200 MG is widely used in modern oncology and may be administered alone or in combination with other chemotherapy medicines depending on the patient's condition and treatment plan.
The medicine is commonly prescribed for:
Gemcitabine has become an important part of cancer treatment worldwide because of its proven clinical effectiveness and broad range of therapeutic applications. It is frequently used in both first-line and subsequent treatment settings for several cancer types.
Manufactured under strict pharmaceutical quality standards, GEMLIEVA RTU 200 MG is designed to provide consistent quality, safety, and therapeutic performance.
Patients receiving Gemcitabine therapy typically require regular blood tests, liver and kidney function assessments, and routine medical evaluations to ensure treatment safety and effectiveness.
Due to its established role in oncology care, GEMLIEVA RTU 200 MG remains a trusted treatment option for patients undergoing chemotherapy for various cancers.
GEMLIEVA RTU 200 MG (Gemcitabine for Injection IP 200 mg) is primarily used in the treatment and management of various solid tumors and advanced malignancies.
Gemcitabine is widely used as a standard treatment option for pancreatic cancer.
The medicine may be prescribed as part of advanced lung cancer treatment protocols.
Doctors may include Gemcitabine in selected breast cancer chemotherapy regimens.
The medicine may be used in patients with recurrent or advanced ovarian cancer.
Gemcitabine is commonly used in chemotherapy programs for bladder cancer.
The medicine may help manage cancers involving the bile ducts and gallbladder.
GEMLIEVA RTU is frequently combined with other anticancer medicines to improve therapeutic outcomes.
The medicine supports comprehensive cancer treatment strategies for various malignancies.
Gemcitabine belongs to a class of medicines known as Antimetabolites.
GEMLIEVA RTU works by:
This mechanism helps control cancer growth and improve treatment effectiveness.
Like all chemotherapy medicines, GEMLIEVA RTU 200 MG may cause side effects in some patients. Side effects vary depending on dosage, treatment duration, and individual patient factors.
Weakness and tiredness are commonly reported during treatment.
Patients may experience mild to moderate nausea.
Episodes of vomiting may occur following administration.
Mild fever may develop during therapy.
Reduced appetite may affect nutritional intake.
Temporary hair thinning or mild hair loss may occur.
Mild skin reactions may develop in some individuals.
Some patients may experience mild breathing difficulties.
The medicine may reduce:
This may increase the risk of infections, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of GEMLIEVA RTU 200 MG (Gemcitabine for Injection IP 200 mg) should always be determined by a qualified oncologist or healthcare professional.
Different cancers require different treatment schedules and protocols.
Dosage is commonly calculated according to body size.
Laboratory results help determine treatment suitability and dosage adjustments.
Organ function assessments may influence treatment planning.
Doctors may modify therapy according to effectiveness and patient tolerance.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
It is used for the treatment of pancreatic cancer, lung cancer, breast cancer, ovarian cancer, bladder cancer, and other advanced solid tumors.
Gemcitabine is an antimetabolite chemotherapy medicine that interferes with DNA synthesis and helps prevent cancer cell growth.
RTU stands for Ready-to-Use, indicating a formulation designed for efficient preparation and administration in clinical settings.
Yes, it is a widely used chemotherapy medicine utilized in modern oncology treatment protocols.
Yes, it is frequently administered as part of combination chemotherapy regimens.
Yes, the medicine may lower blood cell counts, requiring regular laboratory monitoring.
Yes, doctors typically recommend blood tests, liver and kidney assessments, and routine medical evaluations throughout therapy.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology, chemotherapy, and specialized cancer treatment.